Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03346252 · ClinicalTrials.gov registry record · Early Phase 1
The Effect of Botulinum Toxin A on Headache Attributed to TMD
A Early Phase 1 study, sponsored by State University of New York at Buffalo.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT03346252 is a Early Phase 1 study that has completed, run by State University of New York at Buffalo. The registered enrollment target is 20 participants.
The verdict
NCT03346252, a Early Phase 1 study, has completed, sponsored by State University of New York at Buffalo.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study will evaluate the effect of of botulinum toxin on the treatment of Headache Attributed to TMD.
Interventions
- DRUG Botulinum Toxin type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-05-08 |
| Est. Completion | 2021-03-15 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03346252
The ClinicalTrials.gov registry entry for NCT03346252 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York at Buffalo, which has 243 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Botulinum Toxin type A is the first listed.
NCT03346252 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03346252 about?
NCT03346252 is a clinical study titled "The Effect of Botulinum Toxin A on Headache Attributed to TMD". This study will evaluate the effect of of botulinum toxin on the treatment of Headache Attributed to TMD.
What is the current status of trial NCT03346252?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2017-05-08. Estimated completion is 2021-03-15.
What interventions are being tested in trial NCT03346252?
The interventions under investigation include: Botulinum Toxin type A (DRUG).
Who is sponsoring clinical trial NCT03346252?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.